Patents by Inventor Eric Hatterer

Eric Hatterer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bispecific GPC3xCD28 and GPC3xCD3 antibodies and their combination for targeted killing of GPC3 positive malignant cells
    Patent number: 12122850
    Abstract: The present invention relates to GPC3×CD3 bispecific antibodies, GPC3×CD28 bispecific antibodies and the combination of two, agonistic and fully human KA-bodies with one targeting GPC3×CD3 and the other targeting GPC3×CD28, and both not competing for the binding to GPC3. The present invention also relates to the use of the bispecific antibodies for the treatment of GPC3 positive malignancies.
    Type: Grant
    Filed: March 14, 2023
    Date of Patent: October 22, 2024
    Assignee: LamKap Bio gamma AG
    Inventors: Eric Hatterer, Anja Seckinger, Dirk Hose
  • Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of TLR4 ligands and other biomarkers
    Patent number: 10556960
    Abstract: This invention relates generally to methods and compositions for diagnosing and treating disorders associated with elevated levels of Toll-like Receptor 4 (TLR4) ligands and other biomarkers. The invention also relates to methods of treating, delaying the progression of, or otherwise ameliorating a symptom of a disorder associated with elevated levels of TLR4 ligands and other biomarkers using agents that interfere with or otherwise antagonize TLR4 signaling, including neutralizing anti-TLR4 antibodies.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: February 11, 2020
    Assignee: NovImmune SA
    Inventors: Cristina de Min, Limin Shang, Emmanuel Monnet, Greg Elson, Eric Hatterer
  • METHODS AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF DISORDERS IN PATIENTS WITH ELEVATED LEVELS OF TLR4 LIGANDS AND OTHER BIOMARKERS
    Publication number: 20170298140
    Abstract: This invention relates generally to methods and compositions for diagnosing and treating disorders associated with elevated levels of Toll-like Receptor 4 (TLR4) ligands and other biomarkers. The invention also relates to methods of treating, delaying the progression of, or otherwise ameliorating a symptom of a disorder associated with elevated levels of TLR4 ligands and other biomarkers using agents that interfere with or otherwise antagonize TLR4 signaling, including neutralizing anti-TLR4 antibodies.
    Type: Application
    Filed: June 26, 2017
    Publication date: October 19, 2017
    Inventors: Cristina de Min, Limin Shang, Emmanuel Monnet, Greg Elson, Eric Hatterer
  • Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of TLR4 ligands and other biomarkers
    Patent number: 9688769
    Abstract: This invention relates generally to methods and compositions for diagnosing and treating disorders associated with elevated levels of Toll-like Receptor 4 (TLR4) ligands and other biomarkers. The invention also relates to methods of treating, delaying the progression of, or otherwise ameliorating a symptom of a disorder associated with elevated levels of TLR4 ligands and other biomarkers using agents that interfere with or otherwise antagonize TLR4 signaling, including neutralizing anti-TLR4 antibodies.
    Type: Grant
    Filed: October 22, 2014
    Date of Patent: June 27, 2017
    Assignee: NOVIMMUNE S.A.
    Inventors: Christina de Min, Limin Shang, Emmanuel Monnet, Greg Elson, Eric Hatterer
  • METHODS AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF DISORDERS IN PATIENTS WITH ELEVATED LEVELS OF TLR4 LIGANDS AND OTHER BIOMARKERS
    Publication number: 20150110811
    Abstract: This invention relates generally to methods and compositions for diagnosing and treating disorders associated with elevated levels of Toll-like Receptor 4 (TLR4) ligands and other biomarkers. The invention also relates to methods of treating, delaying the progression of, or otherwise ameliorating a symptom of a disorder associated with elevated levels of TLR4 ligands and other biomarkers using agents that interfere with or otherwise antagonize TLR4 signaling, including neutralizing anti-TLR4 antibodies.
    Type: Application
    Filed: October 22, 2014
    Publication date: April 23, 2015
    Inventors: Christina de Min, Limin Shang, Emmanuel Monnet, Greg Elson, Eric Hatterer